Regulation of catabolism of ribonuclease A microinjected into human fibroblasts.

J. F. Dice, Jonathan M. Backer, P. Miao, L. Bourret, M. A. McElligott

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We are using ribonuclease A (RNase A) as a model protein to study how the degradative rates of proteins are regulated within cells. RNase A and several derivatives can be microinjected into confluent cultures of human fibroblasts using red cell-mediated microinjection. The half-life of RNase A is 80-100 hrs in cells maintained in the presence of serum, and the degradative rate is enhanced approximately two-fold upon serum withdrawal. The ability of fibroblasts to regulate breakdown of this protein depends on a small peptide region within the amino terminal twenty amino acids. This amino terminal peptide from RNase A can be covalently attached to unrelated proteins and will cause their catabolism to become serum responsive. The mechanism of degradation of RNase A involves lysosomal pathways both in the presence and absence of serum, and the enhanced catabolism during serum deprivation results from a two-fold increase in the rate of uptake of the protein by lysosomes. These findings suggest that autophagy, or some other process occuring in serum-deprived cells, can be highly selective.

Original languageEnglish (US)
Pages (from-to)385-394
Number of pages10
JournalProgress in Clinical and Biological Research
Volume180
StatePublished - 1985
Externally publishedYes

Fingerprint

Pancreatic Ribonuclease
Fibroblasts
Serum
Proteins
Peptides
Autophagy
Microinjections
Lysosomes
Half-Life
Amino Acids

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Regulation of catabolism of ribonuclease A microinjected into human fibroblasts. / Dice, J. F.; Backer, Jonathan M.; Miao, P.; Bourret, L.; McElligott, M. A.

In: Progress in Clinical and Biological Research, Vol. 180, 1985, p. 385-394.

Research output: Contribution to journalArticle

@article{d2603a3b818e436da9a43d2b224ffda5,
title = "Regulation of catabolism of ribonuclease A microinjected into human fibroblasts.",
abstract = "We are using ribonuclease A (RNase A) as a model protein to study how the degradative rates of proteins are regulated within cells. RNase A and several derivatives can be microinjected into confluent cultures of human fibroblasts using red cell-mediated microinjection. The half-life of RNase A is 80-100 hrs in cells maintained in the presence of serum, and the degradative rate is enhanced approximately two-fold upon serum withdrawal. The ability of fibroblasts to regulate breakdown of this protein depends on a small peptide region within the amino terminal twenty amino acids. This amino terminal peptide from RNase A can be covalently attached to unrelated proteins and will cause their catabolism to become serum responsive. The mechanism of degradation of RNase A involves lysosomal pathways both in the presence and absence of serum, and the enhanced catabolism during serum deprivation results from a two-fold increase in the rate of uptake of the protein by lysosomes. These findings suggest that autophagy, or some other process occuring in serum-deprived cells, can be highly selective.",
author = "Dice, {J. F.} and Backer, {Jonathan M.} and P. Miao and L. Bourret and McElligott, {M. A.}",
year = "1985",
language = "English (US)",
volume = "180",
pages = "385--394",
journal = "Progress in Clinical and Biological Research",
issn = "0361-7742",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Regulation of catabolism of ribonuclease A microinjected into human fibroblasts.

AU - Dice, J. F.

AU - Backer, Jonathan M.

AU - Miao, P.

AU - Bourret, L.

AU - McElligott, M. A.

PY - 1985

Y1 - 1985

N2 - We are using ribonuclease A (RNase A) as a model protein to study how the degradative rates of proteins are regulated within cells. RNase A and several derivatives can be microinjected into confluent cultures of human fibroblasts using red cell-mediated microinjection. The half-life of RNase A is 80-100 hrs in cells maintained in the presence of serum, and the degradative rate is enhanced approximately two-fold upon serum withdrawal. The ability of fibroblasts to regulate breakdown of this protein depends on a small peptide region within the amino terminal twenty amino acids. This amino terminal peptide from RNase A can be covalently attached to unrelated proteins and will cause their catabolism to become serum responsive. The mechanism of degradation of RNase A involves lysosomal pathways both in the presence and absence of serum, and the enhanced catabolism during serum deprivation results from a two-fold increase in the rate of uptake of the protein by lysosomes. These findings suggest that autophagy, or some other process occuring in serum-deprived cells, can be highly selective.

AB - We are using ribonuclease A (RNase A) as a model protein to study how the degradative rates of proteins are regulated within cells. RNase A and several derivatives can be microinjected into confluent cultures of human fibroblasts using red cell-mediated microinjection. The half-life of RNase A is 80-100 hrs in cells maintained in the presence of serum, and the degradative rate is enhanced approximately two-fold upon serum withdrawal. The ability of fibroblasts to regulate breakdown of this protein depends on a small peptide region within the amino terminal twenty amino acids. This amino terminal peptide from RNase A can be covalently attached to unrelated proteins and will cause their catabolism to become serum responsive. The mechanism of degradation of RNase A involves lysosomal pathways both in the presence and absence of serum, and the enhanced catabolism during serum deprivation results from a two-fold increase in the rate of uptake of the protein by lysosomes. These findings suggest that autophagy, or some other process occuring in serum-deprived cells, can be highly selective.

UR - http://www.scopus.com/inward/record.url?scp=0021775921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021775921&partnerID=8YFLogxK

M3 - Article

C2 - 4034548

AN - SCOPUS:0021775921

VL - 180

SP - 385

EP - 394

JO - Progress in Clinical and Biological Research

JF - Progress in Clinical and Biological Research

SN - 0361-7742

ER -